Latest Insider Transactions at Vertex Pharmaceuticals Inc (VRTX)
This section provides a real-time view of insider transactions for Vertex Pharmaceuticals Inc (VRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERTEX PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERTEX PHARMACEUTICALS INC 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 26
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Open market or private sale
|
Direct |
883
-5.24%
|
$375,275
$425.7 P/Share
|
|
Feb 26
2024
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
5,034
-9.2%
|
$2,139,450
$425.7 P/Share
|
|
Feb 26
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
883
-9.98%
|
$375,275
$425.7 P/Share
|
|
Feb 26
2024
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,239
-14.11%
|
$1,801,575
$425.7 P/Share
|
|
Feb 23
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,309
-5.82%
|
$1,426,179
$431.79 P/Share
|
|
Feb 23
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,469
-4.06%
|
$1,064,139
$431.79 P/Share
|
|
Feb 23
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
3,309
-5.56%
|
$1,426,179
$431.79 P/Share
|
|
Feb 23
2024
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
9,386
-6.43%
|
$4,045,366
$431.79 P/Share
|
|
Feb 23
2024
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,309
-8.22%
|
$1,426,179
$431.79 P/Share
|
|
Feb 23
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,654
-8.94%
|
$712,874
$431.79 P/Share
|
|
Feb 23
2024
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,714
-7.93%
|
$2,031,734
$431.79 P/Share
|
|
Feb 23
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
828
-8.56%
|
$356,868
$431.79 P/Share
|
|
Feb 23
2024
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,970
-11.67%
|
$1,711,070
$431.79 P/Share
|
|
Feb 21
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
360
-0.6%
|
$151,560
$421.77 P/Share
|
|
Feb 21
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
3,191
-4.99%
|
$1,343,411
$421.77 P/Share
|
|
Feb 21
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Open market or private sale
|
Direct |
1,201
-6.09%
|
$505,621
$421.77 P/Share
|
|
Feb 21
2024
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,002
-8.11%
|
$1,263,842
$421.77 P/Share
|
|
Feb 21
2024
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
3,603
-5.72%
|
$1,516,863
$421.77 P/Share
|
|
Feb 20
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,812
-4.71%
|
$1,181,040
$420.58 P/Share
|
|
Feb 20
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
480
-0.8%
|
$201,600
$420.79 P/Share
|
|
Feb 20
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
3,373
-5.3%
|
$1,416,660
$420.58 P/Share
|
|
Feb 20
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
4,254
-6.23%
|
$1,786,680
$420.79 P/Share
|
|
Feb 20
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,623
-3.7%
|
$1,101,660
$420.58 P/Share
|
|
Feb 20
2024
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
4,118
-23.01%
|
$1,729,560
$420.58 P/Share
|
|
Feb 20
2024
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
7,019
-4.59%
|
$2,947,980
$420.58 P/Share
|
|
Feb 20
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Open market or private sale
|
Direct |
801
-3.91%
|
$336,420
$420.79 P/Share
|
|
Feb 20
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,125
-5.2%
|
$472,500
$420.58 P/Share
|
|
Feb 20
2024
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,812
-6.53%
|
$1,181,040
$420.58 P/Share
|
|
Feb 20
2024
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
4,804
-7.08%
|
$2,017,680
$420.79 P/Share
|
|
Feb 20
2024
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,373
-4.74%
|
$1,416,660
$420.58 P/Share
|
|
Feb 20
2024
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,002
-9.75%
|
$1,680,840
$420.79 P/Share
|
|
Feb 20
2024
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,812
-6.41%
|
$1,181,040
$420.58 P/Share
|
|
Feb 16
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,750
-5.91%
|
$1,590,000
$424.01 P/Share
|
|
Feb 16
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
4,499
-6.6%
|
$1,907,576
$424.01 P/Share
|
|
Feb 16
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
3,498
-4.7%
|
$1,483,152
$424.01 P/Share
|
|
Feb 16
2024
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
9,359
-5.77%
|
$3,968,216
$424.01 P/Share
|
|
Feb 16
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,501
-6.49%
|
$636,424
$424.01 P/Share
|
|
Feb 16
2024
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,750
-8.01%
|
$1,590,000
$424.01 P/Share
|
|
Feb 16
2024
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,499
-5.94%
|
$1,907,576
$424.01 P/Share
|
|
Feb 16
2024
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,750
-7.88%
|
$1,590,000
$424.01 P/Share
|
|
Feb 15
2024
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
4,655
-20.64%
|
$1,950,445
$419.16 P/Share
|
|
Feb 14
2024
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
4,356
-16.19%
|
$1,825,164
$419.04 P/Share
|
|
Feb 13
2024
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
737
-2.67%
|
$308,803
$419.13 P/Share
|
|
Feb 12
2024
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
2,656
-4.46%
|
$1,112,864
$419.81 P/Share
|
|
Feb 12
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
314
-0.46%
|
$131,880
$420.24 P/Share
|
|
Feb 12
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
3,222
-4.15%
|
$1,353,240
$420.24 P/Share
|
|
Feb 12
2024
|
Jonathan Biller EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,738
-8.68%
|
$726,484
$418.77 P/Share
|
|
Feb 12
2024
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
4,295
-5.37%
|
$1,803,900
$420.24 P/Share
|
|
Feb 12
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Open market or private sale
|
Direct |
913
-3.8%
|
$383,460
$420.24 P/Share
|
|
Feb 12
2024
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,145
-6.2%
|
$1,320,900
$420.24 P/Share
|